You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Medications Research Articles
Popular Medications Research Articles
Highly Recommended Medications Research Articles
Send a link to this page to your friends and colleagues.
DM-99, a drug under development by the Canadian drug company DiaMedica, Inc., has just finished a phase 2a "proof of concept" trial with 40 type 2 patients in Europe. Although the company did not release performance figures from the trial, it found them sufficiently encouraging to move further into phase 2 testing.
DM-99 causes tissues to increase the pace at which they take glucose out of the bloodstream. A DiaMedica spokesman said in a press release that DM-99 may both "insulin sensitize and hasten the onset of insulin action." The results of preclinical testing, announced in early 2008, revealed that DM-99 allowed healthy lab animals to metabolize 41 percent more glucose within an hour of receiving the drug than animals not receiving it.
DiaMedica has a suite of treatments under development for type 2 diabetes, all based on the company's conviction that a dysfunctional nerve signal to the liver is a key contributor to the insulin resistance that characterizes type 2 diabetes. In addition to DM-99, a sister drug, DM-199, which is 40 times more biologically active than DM-99, is scheduled to undergo preclinical testing soon. The company is also in clinical trials with its lead product, DM-71, which has reportedly reduced A1c's and weight, and DM-83, which the company believes may prolong the ability of the pancreas to produce insulin.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.